Searching for the holy grail of a staphylococcal vaccine

Human Vaccines

Volumn 6, Issue 12, 2010, Pages 1068-1070

  Thomsen, Isaac ^a   Dudney, Hannah ^a   Creech, C Buddy ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anti body; Bacterial vaccine; Colonization; MRSA; S. aureus; Staphylococcal vaccine

Indexed keywords

BACTERIAL TOXIN; PANTON VALENTINE LEUKOCIDIN; STAPHYLOCOCCUS ENTEROTOXIN A; STAPHYLOCOCCUS VACCINE; TOXIC SHOCK SYNDROME TOXIN 1;

ADAPTIVE IMMUNITY; ANTIBODY RESPONSE; ANTIBODY TITER; BACTERIUM COLONY; DISEASE CARRIER; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; INFECTION PREVENTION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; NOTE; STAPHYLOCOCCAL PNEUMONIA; STAPHYLOCOCCUS INFECTION; UNITED STATES;

EID: 78751652217     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.6.12.12917     Document Type: Note

References (40)

1. Klevens RM, Morrison MA, Nadle J, Petit S, Gershman K, Ray S, et al. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA 2007; 298:13-6.
2. Nouwen JL, Ott A, Kluytmans-Vandenbergh MF, et al. Predicting the Staphylococcus aureus nasal carrier state: derivation and validation of a "culture rule". Clin Infect Dis 2004; 39:806-11.
3. Kluytmans J, van Belkum A, Verbrugh H. Nasal carriage of Staphylococcus aureus: epidemiology, underlying mechanisms and associated risks. Clin Microbiol Rev 1997; 10:505-20.
4. rd rev. Ed. Philadelphia, PA: Churchill Livingstone/Elsevier 2008.
5. Plotkin SA. Vaccines: past, present and future. Nat Med 2005; 11:5-11.
6. Williams RE. Healthy carriage of Staphylococcus aureus: its prevalence and importance. Bacteriol Rev 1963; 27:56-71.
7. Armstrong-Esther CA. Carriage patterns of Staphylococcus aureus in a healthy non-hospital population of adults and children. Ann Hum Biol 1976; 3:221-7.
8. Eriksen NH, Espersen F, Rosdahl VT, Jensen K. Carriage of Staphylococcus aureus among 104 healthy persons during a 19 month period. Epidemiol Infect 1995; 115:51-60.
9. VandenBergh MF, Yzerman EP, van Belkum A, Boelens HA, Sijmons M, Verbrugh HA. Follow-up of Staphylococcus aureus nasal carriage after 8 years: redefining the persistent carrier state. J Clin Microbiol 1999; 37:3133-40.
10. Nouwen JL, Fieren MW, Snijders S, Verbrugh HA, van Belkum A. Persistent (not intermittent) nasal carriage of Staphylococcus aureus is the determinant of CPD-related infections. Kidney Int 2005; 67:1084-92. (Pubitemid 41623334)
11. von Eiff C, Becker K, Machka K, Stammer H, Peters G. Nasal carriage as a source of Staphylococcus aureus bacteremia. Study Group. N Engl J Med 2001; 344:11-6.
12. Wertheim HF, Vos MC, Ott A, van Belkum A, Voss A, Kluytmans JA, et al. Risk and outcome of nosocomial Staphylococcus aureus bacteraemia in nasal carriers versus non-carriers. Lancet 2004; 364:703-5. (Pubitemid 39140626)
13. Verkaik NJ, de Vogel CP, Boelens HA, et al. Antistaphylococcal humoral immune response in persistent nasal carriers and noncarriers of Staphylococcus aureus. J Infect Dis 2009; 199:625-32.
14. Ritz HL, Kirkland JJ, Bond GG, Warner EK, Petty GP. Association of high levels of serum antibody to staphylococcal toxic shock antigen with nasal carriage of toxic shock antigen-producing strains of Staphylococcus aureus. Infect Immun 1984; 43:954-8.
15. Strandvik B, Hollsing A, Mollby R, Granstrom M. Antistaphylococcal antibodies in cystic fibrosis. Infection 1990; 18:170-2.
16. Dryla A, Prustomersky S, Gelbmann D, Hanner M, Bettinger E, Kocsis B, et al. Comparison of antibody repertoires against Staphylococcus aureus in healthy individuals and in acutely infected patients. Clin Diagn Lab Immunol 2005; 12:387-98.
17. Holtfreter S, Broker BM. Staphylococcal superantigens: do they play a role in sepsis? Arch Immunol Ther Exp (Warsz) 2005; 53:13-27.
18. Holtfreter S, Roschack K, Eichler P, Eske K, Holtfreter B, Kohler C, et al. Staphylococcus aureus carriers neutralize superantigens by antibodies specific for their colonizing strain: a potential explanation for their improved prognosis in severe sepsis. J Infect Dis 2006; 193:1275-8.
19. Creech CB, 2nd, Johnson BG, Alsentzer AR, Hohenboken M, Edwards KM, Talbot TR, 3rd. Vaccination as infection control: a pilot study to determine the impact of Staphylococcus aureus vaccination on nasal carriage. Vaccine 2009; 28:256-60.
20. Holtfreter S, Nguyen TT, Wertheim H, Steil L, Kusch H, Truong QP, et al. Human immune proteome in experimental colonization with Staphylococcus aureus. Clin Vaccine Immunol 2009; 16:1607-14.
21. Flock JI. Extracellular-matrix-binding proteins as targets for the prevention of Staphylococcus aureus infections. Mol Med Today 1999; 5:532-7.
22. Josefsson E, Hartford O, O'Brien L, Patti JM, Foster T. Protection against experimental Staphylococcus aureus arthritis by vaccination with clumping factor A, a novel virulence determinant. J Infect Dis 2001; 184:1572-80.
23. Kuklin NA, Clark DJ, Secore S, Cook J, Cope LD, McNeely T, et al. A novel Staphylococcus aureus vaccine: iron surface determinant B induces rapid antibody responses in rhesus macaques and specific increased survival in a murine S. aureus sepsis model. Infect Immun 2006; 74:2215-23.
24. Stranger-Jones YK, Bae T, Schneewind O. Vaccine assembly from surface proteins of Staphylococcus aureus. Proc Natl Acad Sci USA 2006; 103:16942-7.
25. Rennermalm A, Li YH, Bohaufs L, Jarstrand C, Brauner A, Brennan FR, et al. Antibodies against a truncated Staphylococcus aureus fibronectin-binding protein protect against dissemination of infection in the rat. Vaccine 2001; 19:3376-83. (Pubitemid 32710286)
26. Holtfreter S, Kolata J, Broker BM. Towards the immune proteome of Staphylococcus aureus - The anti-S. aureus antibody response. Int J Med Microbiol 2009.
27. Langley R, Wines B, Willoughby N, Basu I, Proft T, Fraser JD. The staphylococcal superantigen-like protein 7 binds IgA and complement C5 and inhibits IgA-Fcalpha RI binding and serum killing of bacteria. J Immunol 2005; 174:2926-33. (Pubitemid 40279711)
28. Colque-Navarro P, Soderquist B, Holmberg H, Blomqvist L, Olcen P, Mollby R. Antibody response in Staphylococcus aureus septicaemia - a prospective study. J Med Microbiol 1998; 47:217-25. (Pubitemid 28090051)
29. Ryding U, Christensson B, Soderquist B, Wadstrom T. Antibody response to Staphylococcus aureus collagen binding protein in patients with S. aureus septicaemia and collagen binding properties of corresponding strains. J Med Microbiol 1995; 43:328-34.
30. Clarke SR, Foster SJ. Surface adhesins of Staphylococcus aureus. Adv Microb Physiol 2006; 51:187-224.
31. Casolini F, Visai L, Joh D, et al. Antibody response to fibronectin-binding adhesin FnbpA in patients with Staphylococcus aureus infections. Infect Immun 1998; 66:5433-42. (Pubitemid 29044641)
32. Colque-Navarro P, Palma M, Soderquist B, Flock JI, Mollby R. Antibody responses in patients with staphylococcal septicemia against two Staphylococcus aureus fibrinogen binding proteins: clumping factor and an extracellular fibrinogen binding protein. Clin Diagn Lab Immunol 2000; 7:14-20.
33. Cremieux AC, Dumitrescu O, Lina G, et al. Pantonvalentine leukocidin enhances the severity of community-associated methicillin-resistant Staphylococcus aureus rabbit osteomyelitis. PLoS One 2009; 4:7204.
34. Voyich JM, Otto M, Mathema B, et al. Is Panton-Valentine leukocidin the major virulence determinant in community-associated methicillin-resistant Staphylococcus aureus disease? J Infect Dis 2006; 194:1761-70.
35. Lina G, Piemont Y, Godail-Gamot F, et al. Involvement of Panton-Valentine leukocidin-producing Staphylococcus aureus in primary skin infections and pneumonia. Clin Infect Dis 1999; 29:1128-32.
36. Croze M, Dauwalder O, Dumitrescu O, et al. Serum antibodies against Panton-Valentine leukocidin in a normal population and during Staphylococcus aureus infection. Clin Microbiol Infect 2009; 15:144-8.
37. Brown EL, Bowden MG, Bryson RS, et al. Pediatric antibody response to community-acquired Staphylococcus aureus infection is directed to Panton-Valentine leukocidin. Clin Vaccine Immunol 2009; 16:139-41.
38. Yoong P, Pier GB. Antibody-mediated enhancement of community-acquired methicillin-resistant Staphylococcus aureus infection. Proc Natl Acad Sci USA 2010; 107:2241-6.
39. Lindsay JA, Holden MT. Understanding the rise of the superbug: investigation of the evolution and genomic variation of Staphylococcus aureus. Funct Integr Genomics 2006; 6:186-201.
40. Plotkin SA. Vaccines: correlates of vaccine-induced immunity. Clin Infect Dis 2008; 47:401-9.